Press Releases April 27, 2026 08:31 AM

Consolidated Water Sets Investor Conference Call to Discuss First Quarter 2026 Results on Tuesday, May 12, 2026 at 11:00 a.m. ET

Consolidated Water announces Q1 2026 earnings conference call schedule

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
CWCO

Consolidated Water Co. Ltd., a leading water treatment plant designer and operator, will release its Q1 2026 financial results and hold a conference call on May 12, 2026. The company operates seawater desalination and water treatment facilities primarily in the Caribbean and the United States.

Consolidated Water Sets Investor Conference Call to Discuss First Quarter 2026 Results on Tuesday, May 12, 2026 at 11:00 a.m. ET
CWCO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Conference call scheduled for May 12, 2026, to discuss Q1 results ending March 31, 2026.
  • Consolidated Water operates advanced seawater desalination and water treatment plants in the Cayman Islands, Bahamas, British Virgin Islands, and the US.
  • Company also provides water treatment product manufacturing and various engineering and management services.

GEORGE TOWN, Cayman Islands, April 27, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, will hold a conference call on Tuesday, May 12, 2026 at 11:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2026.

The financial results will be issued in a press release prior to the call. Consolidated Water management will host the call, followed by a question-and-answer period.

Date: Tuesday, May 12, 2026
Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time)
Toll-free dial-in number: 1-844-875-6913
International dial-in number: 1-412-317-6709
Participant web phone: click here
Conference ID: 3191190

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you require any assistance connecting with the call, please contact Encore at 1-949-432-7450.

A replay of the call will be available after 1:00 p.m. Eastern time on the same day through May 19, 2026, as well as available for replay via the Investors section of the Consolidated Water website at www.cwco.com.

Toll-free replay number: 1-855-669-9658
International replay number: 1-412-317-0088
Replay ID: 3191190

About Consolidated Water Co. Ltd.
Consolidated Water Co. Ltd. develops and operates advanced water treatment plants and water distribution systems. The company designs, constructs and operates seawater desalination facilities in the Cayman Islands, The Bahamas and the British Virgin Islands, and designs, constructs and operates water treatment and reuse facilities in the United States.

The company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment.

For more information, visit cwco.com.

Company Contact:
David W. Sasnett
Executive Vice President and CFO
Tel (954) 509-8200
Email Contact

Investor & Media Contact:
Ron Both or Grant Stude
Encore Investor Relations
Tel (949) 432-7450
Email Contact


Risks

  • Potential financial performance uncertainties impacting investor expectations pending Q1 results.
  • Operational risks related to water treatment and desalination plant performance and maintenance.
  • Market risks from economic conditions in the Caribbean and US affecting water infrastructure investments.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026